Screener
Monopar Therapeutics MNPR Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | March 31, 2026 | December 31, 2025* |
|---|---|---|
| Accounts payable, accrued expenses and other current liabilities | $2,457,748 | $2,735,236 |
| Total current liabilities | 2,457,748 | 2,735,236 |
| Non-current operating lease liability | 131,565 | 154,920 |
| Total liabilities | 2,589,313 | 2,890,156 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 6,699,062 and 6,692,140 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively | 6,699 | 6,692 |
| Additional paid-in capital | 228,691,772 | 227,199,002 |
Document
FAQ
- What is Monopar Therapeutics's total liabilities?
- Monopar Therapeutics (MNPR) reported total liabilities of $2.59M in Q1 2026.
- How has Monopar Therapeutics's total liabilities changed year-over-year?
- Monopar Therapeutics's total liabilities increased by 73.6% year-over-year, from $1.49M to $2.59M.
- What is the long-term trend for Monopar Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Monopar Therapeutics's total liabilities has grown at a 19.7% compound annual growth rate (CAGR), from $1.18M to $2.89M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Monopar Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude